Susquehanna International Group
KLRA

Susquehanna International Group’s Kailera Therapeutics KLRA Stock Holding History

Susquehanna International Group’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$718K Buy
+32,609
New +$717K ﹤0.01% 9041

Other funds holding KLRA

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group's KLRA Position: Q2 2026 in Review

Susquehanna International Group opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 32,609 shares worth $718K. The stake represents ﹤0.01% of the portfolio and ranks #9041 among its holdings.

79 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Susquehanna International Group held 32,609 shares of Kailera Therapeutics worth $718K as of Q2 2026.
  • Kailera Therapeutics was a new Susquehanna International Group position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #9041 holding.
  • 79 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.